Maxillectomy and targeted radionuclide therapy with 153Sm‐EDTMP in a recurrent canine osteosarcoma

Moe, Lars; Boysen, Morten; Aas, Magne; Lønaas, L.; Gamlem, Hans; Bruland, Øyvind S.

doi:10.1111/j.1748-5827.1996.tb01782.x

Cited by 14 publications

(13 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These findings are in agreement with reports in the literature on the effects of Sm-153-EDTMP on blood parameters 12,13,19 .…”

Section: Resultssupporting

confidence: 83%

“…Evaluation of Sm-153-EDTMP combined with other treatment modalities, as reported by Moe et al 19 , may hold more promise, as well as investigation into other beta-emitting radio-pharmaceuticals 14,16 . The right scapula nevertheless showed more up-take than the opposite scapula.…”

Section: Resultsmentioning

confidence: 99%

“…Moe et al 19 described treatment of an osteosarcoma of the maxilla with Sm-153-EDTMP combined with surgical debulking of the mass. No local recurrence or metastases were evident 21 months postsurgery.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Targeted radiotherapy with Sm-153-EDTMP in nine cases of canine primary bone tumours

Milner¹,

Dormehl²,

Louw³

et al. 1998

J. S. Afr. Vet. Assoc.

View full text Add to dashboard Cite

Nine dogs with primary bone tumours were treated with Samarium-153-EDTMP (Sm-153- EDTMP). Conventional treatment protocols were precluded by the size of the dogs and the owners' refusal of limb amputation. All the tumours were of the appendicular skeleton; 4 were confirmed osteosarcomas. The other 5 tumours were radiologically suspect for osteosarcoma. Bone scans were performed on all dogs using Technetium-99m-methylene diphosphonate (Tc-99m-MDP) before administration of Sm-153-EDTMP. Regions of interest were identified over the contralateral limb at the same site as the tumour and counts per pixel were recorded for the tumour and contralateral limb and expressed as a ratio. The dogs were given 1 injection of 37 MBq/kg (1 mCi/kg) of Sm-153-EDTMP intravenously. Thoracic and primary tumour site radiographs were taken at monthly or 2-monthly intervals to monitor progression of the primary tumour and search for evidence of metastasis. Two dogs showed no response to treatment, with an increase in bone pain, and were euthanased within 1 month. In 1 dog, a tumour of the scapula underwent complete involution and the dog is considered free of disease at 20 months post Sm-153-EDTMP treatment. The overall tumourcidal effect of a single dose of Sm-153-EDTMP on primary bone tumours was difficult to evaluate in this group of dogs, as, with one exception, all the primary tumours progressed over time and the dogs were euthanased. Pain control, for which Sm-155-EDTMP is used in man, was not evident, except in the dog that responded completely to treatment

show abstract

“…These findings are in agreement with reports in the literature on the effects of Sm-153-EDTMP on blood parameters 12,13,19 .…”

Section: Resultssupporting

confidence: 83%

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Targeted radiotherapy with Sm-153-EDTMP in nine cases of canine primary bone tumours

Milner¹,

Dormehl²,

Louw³

et al. 1998

J. S. Afr. Vet. Assoc.

View full text Add to dashboard Cite

show abstract

“…This agent was initially developed to treat painful bone metastasis, usually in the setting of palliation for diseases like prostate and breast cancer 63 . Brulan and colleagues proved the principal that this agent could be used for osteosarcoma using the companion canine model, an observation confirmed by other studies 64-66 . Subsequently, Pete Anderson and others have shown the utility of this agent in treating human osteosarcoma 67-69 .…”

Section: Samarium and Bisphosphonatesmentioning

confidence: 65%

Strategies for the targeted delivery of therapeutics for osteosarcoma

Hughes

2009

Expert Opinion on Drug Delivery

View full text Add to dashboard Cite

Background Conventional therapy for osteosarcoma has reached a plateau of 60-70%, a five-year survival rate that has changed little in two decades, highlighting the need for new approaches. Objective I wished to review the alternate means of delivering effective therapy for osteosarcoma that reach beyond the central venous catheter. Methods Drawing on my own experiences providing care to high-risk osteosarcoma patients and reviewing the last two decades of literature describing sarcoma therapy, I summarize available information about potential osteosarcoma treatments that deliver therapy by a less conventional route. Results/Conclusions Intra-arterial chemotherapy has a limited impact on survival, but may help achieve a better limb salvage. Intrapleural chemotherapy is important for managing malignant effusions. Development of inhalation therapies, treatments that target new bone formation such as bisphosphonates, chemically targeted radiation and antibody-based therapies all have potential to improve osteosarcoma therapy.

show abstract

“…In addition, 153 Sm-EDTMP has also been shown to slow the progression of metastatic disease, due to eradication of smaller lesions [10,11]. Canine studies and limited studies in people have suggested that 153 Sm-EDTMP may also be an effective component of a multi-modality treatment regimen for primary bone tumors [2,[12][13][14][15][16][17]. A clinical trial by Lattimer et al was the first published study that evaluated the therapeutic efficacy that a single or double injection of 153 Sm-EDTMP had on the regression of primary bone tumors [2].…”

mentioning

confidence: 99%

The Use of the Bone Seeking Radiopharmaceutical 153-Samarium-EDTMP as an Adjuvant Treatment for Osteosarcoma: A Review

Essman¹

2007

CMIR

View full text Add to dashboard Cite

The use of the bone seeking radiopharmaceutical samarium-153-ethylenediaminetetramethylene phosphonate ( 153 Sm-EDTMP) for the treatment of bone pain secondary to osseous metastatic disease has increased in popularity over the past decade. The success of this treatment has opened new possibilities for the application of this agent as a component of a multi-modality treatment regimen for primary bone tumors. Targeted radiotherapy using 153 Sm-EDTMP is currently under investigation for treatment of osteosarcoma. Osteosarcoma often occurs in skeletally immature individuals; however, the overall effects 153 Sm-EDTMP on skeletal growth have yet to be determined. This review discusses the use of 153 Sm-EDTMP as an adjuvant treatment for primary bone tumors. In addition, preliminary studies have been performed to determine the effects that 153 Sm-EDTMP may have on skeletal growth and physeal cartilage development in a juvenile rabbit model and these results are discussed.

show abstract

Maxillectomy and targeted radionuclide therapy with 153Sm‐EDTMP in a recurrent canine osteosarcoma

Cited by 14 publications

References 10 publications

Targeted radiotherapy with Sm-153-EDTMP in nine cases of canine primary bone tumours

Targeted radiotherapy with Sm-153-EDTMP in nine cases of canine primary bone tumours

Strategies for the targeted delivery of therapeutics for osteosarcoma

The Use of the Bone Seeking Radiopharmaceutical 153-Samarium-EDTMP as an Adjuvant Treatment for Osteosarcoma: A Review

Contact Info

Product

Resources

About